Table 1.
Patient and treatment characteristics for different treatment groups.
| Before propensity matching | After propensity matching | |||||||
|---|---|---|---|---|---|---|---|---|
| Factor | Level | SBRT | TACE | p-value | SBRT | TACE | p-value | Test |
| Number of patients | 167 | 159 | 95 | 95 | ||||
| Gender | Male | 141 (84.4%) | 139 (87.4%) | 0.44 | 83 (87%) | 84 (88%) | 0.82 | Pearson's chi-squared |
| Age, median (IQR) | 56 (47, 65) | 52 (44, 61) | 0.007 | 55 (45, 63) | 52 (44, 63) | 0.31 | Wilcoxon rank-sum | |
| Age | >/=60 | 70 (41.9%) | 49 (30.8%) | 0.037 | 36 (38%) | 29 (31%) | 0.28 | Pearson's chi-squared |
| HBV | Positive | 145 (86.8%) | 141 (88.7%) | 0.61 | 83 (87%) | 84 (88%) | 0.82 | Pearso's chi-squared |
| Negative | 22 (13.2%) | 18 (11.3%) | 12 (13%) | 11 (12%) | ||||
| Tbil, median (IQR) | 13.3 (9.3, 20.1) | 14.4 (9.3, 21.5) | 0.48 | 13.4 (9.7, 20.5) | 14.9 (9.3, 22.4) | 0.52 | Wilcoxon rank-sum | |
| Albumin, median (IQR) | 37.9 (34.5, 41.7) | 38.7 (34.2, 42) | 0.63 | 37.6 (34.4, 41.8) | 39.3 (33.9, 42.3) | 0.26 | Wilcoxon rank-sum | |
| ALT, median (IQR) | 31 (21, 44) | 44 (35, 82) | <0.001 | 35 (23, 50) | 39 (32, 60) | 0.1 | Wilcoxon rank-sum | |
| AST, median (IQR) | 31 (21, 50) | 35 (24, 53) | 0.13 | 36 (23, 52) | 31 (22, 43) | 0.24 | Wilcoxon rank-sum | |
| PT, median (IQR) | 13.2 (12.5, 14) | 13.1 (12.3, 14.4) | 0.97 | 13.1 (12.5, 14.1) | 13.3 (12.4, 14.8) | 0.41 | Wilcoxon rank-sum | |
| Size, median (IQR) | 3.4 (2.4, 5.2) | 7.2 (4.2, 12.1) | <0.001 | 4.5 (3, 6.7) | 5 (3, 7.1) | 0.6 | Wilcoxon rank-sum | |
| Size status | 1–5 cm | 123 (73.7%) | 53 (33.3%) | <0.001 | 53 (56%) | 49 (52%) | 0.47 | Pearson's chi-squared |
| 5–10 cm | 40 (24.0%) | 54 (34.0%) | 38 (40%) | 38 (40%) | ||||
| 10–19.5 cm | 4 (2.4%) | 52 (32.7%) | 4 (4%) | 8 (8%) | ||||
| ALBI score, median (IQR) | −2.519 (−2.802, −2.179) | −2.511 (−2.878, −2.127) | 0.88 | −2.515 (−2.761, −2.127) | −2.530 (−2.967, −2.088) | 0.5 | Wilcoxon rank-sum | |
| ALBI grade | 1 | 73 (43.7%) | 64 (40.3%) | 0.48 | 41 (43%) | 40 (42%) | 0.29 | Pearson's chi-squared |
| 2 | 88 (52.7%) | 85 (53.5%) | 51 (54%) | 47 (49%) | ||||
| 3 | 6 (3.6%) | 10 (6.3%) | 3 (3%) | 8 (8%) | ||||
| Child–Pugh score | 5 | 105 (62.9%) | 118 (74.2%) | 0.2 | 59 (62%) | 70 (74%) | 0.24 | Pearson's chi-squared |
| 6 | 32 (19.2%) | 21 (13.2%) | 17 (18%) | 11 (12%) | ||||
| 7 | 18 (10.8%) | 9 (5.7%) | 12 (13%) | 5 (5%) | ||||
| 8 | 5 (3.0%) | 4 (2.5%) | 3 (3%) | 3 (3%) | ||||
| 9 | 7 (4.2%) | 7 (4.4%) | 4 (4%) | 6 (6%) | ||||
| Child–Pugh class | A | 137 (82.0%) | 139 (87.4%) | 0.18 | 76 (80%) | 81 (85%) | 0.34 | Pearson's chi-squared |
| B | 30 (18.0%) | 20 (12.6%) | 19 (20%) | 14 (15%) | ||||
| AFP | 0–7 | 58 (34.7%) | 35 (22.0%) | 0.013 | 28 (29%) | 22 (23%) | 0.61 | Pearson's chi-squared |
| >7–100 | 50 (29.9%) | 42 (26.4%) | 23 (24%) | 28 (29%) | ||||
| >100–400 | 20 (12.0%) | 22 (13.8%) | 15 (16%) | 12 (13%) | ||||
| >400 | 39 (23.4%) | 60 (37.7%) | 29 (31%) | 33 (35%) | ||||
ALBI, albumin–bilirubin; AFP, alpha fetoprotein; TACE, transarterial embolization; SBRT, stereotactic body radiation therapy; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase.